{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:50:02Z","timestamp":1792410602067,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To correlate choroidal structure parameters with the presence and amount of subretinal fluid (SRF) and intraretinal fluid (IRF) in treatment-na\u00efve neovascular age-related macular degeneration (nAMD) patients with type 1 macular neovascularisation (MNV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective study reviewed clinical records of 96 patients diagnosed with nAMD between 2015 and 2022. Optical coherence tomography (OCT) scans were analysed for choroidal thickness, choroidal vascularity index (CVI), and large choroidal vessel index (LCVI) using ImageJ software with automated binarisation. SRF was manually quantified using embedded OCT tools, and IRF volume was measured using an artificial intelligence-based platform. Patients with type 1 MNV (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200956) were included for fluid-choroidal correlations. Statistical analyses included t-tests, Mann-Whitney U tests, and Spearman correlations (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In type 1 MNV eyes, SRF presence was associated with greater choroidal thickness (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), and SRF area correlated positively with choroidal thickness (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02) and foveal LCVI (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004). Maximum SRF height correlated with foveal LCVI (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007). IRF presence was linked to reduced choroidal thickness (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0008), and IRF volume inversely correlated with choroidal thickness (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01) and macular LCVI (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). No significant choroidal changes were observed pre-MNV or compared to fellow eyes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In treatment-na\u00efve type 1 MNV, choroidal thickness and LCVI exhibit opposite associations with subretinal and intraretinal fluid, emphasising distinct pathophysiological mechanisms: choroidal venous overload may be associated with SRF accumulation, while choroidal thinning may be implicated in IRF formation. These findings may help generate hypothesis regarding variability in anti-VEGF treatment response and suggest that choroidal characteristics warrant further investigation as potential biomarkers for future individualised management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04825-2","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:50:41Z","timestamp":1789969841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between choroidal structure and retinal fluid location in type 1 neovascular age-related macular degeneration"],"prefix":"10.1038","author":[{"given":"Valentina","family":"Bilbao-Malav\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5840-0149","authenticated-orcid":false,"given":"Miriam","family":"de la Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyre","family":"Ochoa-Tejada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Irigoyen Ba\u00f1egil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Anduaga-Beramendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Fraga de la Viesca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Llorente-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"S\u00e1enz de Viteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henar","family":"Heras-Mulero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7041-5576","authenticated-orcid":false,"given":"Luis","family":"Arias-Barquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Garc\u00eda-Layana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Recalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Gonz\u00e1lez-Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"4825_CR1","volume":"14","author":"H Vyawahare","year":"2022","unstructured":"Vyawahare H, Shinde P. Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment. Cureus. 2022;14:e29583.","journal-title":"Cureus"},{"key":"4825_CR2","doi-asserted-by":"crossref","unstructured":"Cheng S, Zhang S, Huang M, Liu Y, Zou X, Chen X, et al. Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications. Front Med. 2024;11. Available from: https:\/\/www.frontiersin.org\/journals\/medicine\/articles\/10.3389\/fmed.2024.1411278\/full","DOI":"10.3389\/fmed.2024.1411278"},{"key":"4825_CR3","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/aos.14786","volume":"99","author":"M S\u00e1enz-de-Viteri","year":"2021","unstructured":"S\u00e1enz-de-Viteri M, Recalde S, Fern\u00e1ndez-Robredo P, L\u00f3pez G\u00e1lvez MI, Arias Barquet L, Figueroa MS, et al. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the in-Eye study. Acta Ophthalmol. 2021;99:861\u201370","journal-title":"Acta Ophthalmol"},{"key":"4825_CR4","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1111\/aos.14905","volume":"100","author":"S Llorente-Gonz\u00e1lez","year":"2022","unstructured":"Llorente-Gonz\u00e1lez S, Hern\u00e1ndez, Gonz\u00e1lez-Zamora J, Bilbao-Malav\u00e9 V, Fern\u00e1ndez-Robredo P, S\u00e1enz-de-Viteri M, et al. The role of retinal fluid location in atrophy and fibrosis evolution of patients with neovascular age-related macular degeneration long-term treated in real world. Acta Ophthalmol. 2022;100:e521\u201331.","journal-title":"Acta Ophthalmol"},{"key":"4825_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100973","volume":"86","author":"RF Spaide","year":"2022","unstructured":"Spaide RF, Gemmy Cheung CM, Matsumoto H, Kishi S, Boon CJF, van Dijk EHC, et al. Venous overload choroidopathy: a hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retinal Eye Res. 2022;86:100973.","journal-title":"Prog Retinal Eye Res"},{"key":"4825_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72\u201384.","journal-title":"Ophthalmology"},{"key":"4825_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193\u2013201.","journal-title":"Ophthalmology"},{"key":"4825_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2021.06.029","volume":"233","author":"NM Holekamp","year":"2022","unstructured":"Holekamp NM, Sadda S, Sarraf D, Guymer R, Hill L, Blotner S, et al. Effect of residual retinal fluid on visual function in ranibizumab-treated neovascular age-related macular degeneration. Am J Ophthalmol. 2022;233:8\u201317.","journal-title":"Am J Ophthalmol"},{"key":"4825_CR9","doi-asserted-by":"crossref","unstructured":"Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al.Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388\u201398.","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"4825_CR10","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/s41433-022-02231-y","volume":"37","author":"T Mathis","year":"2023","unstructured":"Mathis T, Holz FG, Sivaprasad S, Yoon YH, Eter N, Chen LJ, et al. Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes. Eye. 2023;37:1758\u201365.","journal-title":"Eye"},{"key":"4825_CR11","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1097\/IAE.0000000000001312","volume":"37","author":"X Wei","year":"2017","unstructured":"Wei X, Ting DSW, Ng WY, Khandelwal N, Agrawal R, Cheung CMG. Choroidal vascularity index: a novel optical coherence tomography-based parameter in patients with exudative age-related macular degeneration. Retina. 2017;37:1120\u20135.","journal-title":"Retina"},{"key":"4825_CR12","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/s41433-021-01487-0","volume":"35","author":"L Kodjikian","year":"2021","unstructured":"Kodjikian L, Parravano M, Clemens A, Dolz-Marco R, Holz FG, Munk MR, et al. Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations. Eye. 2021;35:2119\u201335.","journal-title":"Eye"},{"key":"4825_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40123-025-01093-3","volume":"14","author":"AJE Foss","year":"2025","unstructured":"Foss AJE, Almeida D, Cheung CMG, Ogura Y, de Cock E, Empeslidis T. To treat or not to treat? Resolving the question of subretinal and intraretinal fluid in age-related macular degeneration: a narrative review. Ophthalmol Ther. 2025;14:489\u2013514.","journal-title":"Ophthalmol Ther"},{"key":"4825_CR14","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","volume":"126","author":"RH Guymer","year":"2019","unstructured":"Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ, et al. Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen. Ophthalmology. 2019;126:723\u201334.","journal-title":"Ophthalmology"},{"key":"4825_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.oret.2019.05.009","volume":"3","author":"Y Chantarasorn","year":"2019","unstructured":"Chantarasorn Y, Oellers P, Eliott D. Choroidal thickness is associated with delayed subretinal fluid absorption after rhegmatogenous retinal detachment surgery. Ophthalmol Retin. 2019;3:947\u201355.","journal-title":"Ophthalmol Retin"},{"key":"4825_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/ceo.13732","volume":"48","author":"DRW Fuzzard","year":"2020","unstructured":"Fuzzard DRW, Gin TJ, Hardy TG, Harper CA. Subretinal fluid and choroidal venous congestion secondary to a presumed dural cavernous sinus fistula. Clin Exp Ophthalmol. 2020;48:517\u20139.","journal-title":"Clin Exp Ophthalmol"},{"key":"4825_CR17","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1097\/IAE.0000000000001040","volume":"36","author":"R Agrawal","year":"2016","unstructured":"Agrawal R, Chhablani J, Tan KA, Shah S, Sarvaiya C, Banker A. Choroidal vascularity index in central serous chorioretinopathy. Retina. 2016;36:1646\u201351.","journal-title":"Retina"},{"key":"4825_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46235-3","volume":"9","author":"K Bae","year":"2019","unstructured":"Bae K, Noh SR, Kang SW, Kim ES, Yu SY. Angiographic subtypes of neovascular age-related macular degeneration in Korean: a new diagnostic challenge. Sci Rep. 2019;9:9701.","journal-title":"Sci Rep"},{"key":"4825_CR19","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1167\/iovs.18-23960","volume":"59","author":"A Invernizzi","year":"2018","unstructured":"Invernizzi A, Benatti E, Cozzi M, Erba S, Vaishnavi S, Vupparaboina KK, et al. Choroidal structural changes correlate with neovascular activity in neovascular age-relatedmacular degeneration. Investig Ophthalmol Vis Sci. 2018;59:3836\u201341.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4825_CR20","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1111\/aos.15219","volume":"101","author":"M Schranz","year":"2023","unstructured":"Schranz M, Told R, Hacker V, Reiter GS, Reumueller A, Vogl WD, et al. Correlation of vascular and fluid-related parameters in neovascular age-related macular degeneration using deep learning. Acta Ophthalmol. 2023;101:e95\u2013105.","journal-title":"Acta Ophthalmol"},{"key":"4825_CR21","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.oret.2021.06.003","volume":"5","author":"JQ Core","year":"2021","unstructured":"Core JQ, Pistilli M, Daniel E, Grunwald JE, Toth CA, Jaffe GJ, et al. Predominantly persistent subretinal fluid in the comparison of age-related macular degeneration treatments trials. Ophthalmol Retin. 2021;5:962\u201374.","journal-title":"Ophthalmol Retin"},{"key":"4825_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/ceo.14225","volume":"51","author":"EE Cornish","year":"2023","unstructured":"Cornish EE, Zagora SL, Spooner K, Fraser-Bell S. Management of macular oedema due to retinal vein occlusion: an evidence-based systematic review and meta-analysis. Clin Exp Ophthalmol. 2023;51:313\u201338.","journal-title":"Clin Exp Ophthalmol"},{"key":"4825_CR23","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/eye.2016.115","volume":"30","author":"C Fardeau","year":"2016","unstructured":"Fardeau C, Champion E, Massamba N, LeHoang P. Uveitic macular edema. Eye. 2016;30:1277\u201392.","journal-title":"Eye"},{"key":"4825_CR24","doi-asserted-by":"crossref","unstructured":"Haydinger CD, Ferreira LB, Williams KA, Smith JR. Mechanisms of macular edema. Front Med. 2023;10. Available from: https:\/\/www.frontiersin.org\/journals\/medicine\/articles\/10.3389\/fmed.2023.1128811\/full","DOI":"10.3389\/fmed.2023.1128811"},{"key":"4825_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00603-y","volume":"10","author":"ASA Sakini","year":"2024","unstructured":"Sakini ASA, Hamid AK, Alkhuzaie ZA, Al-Aish ST, Al-Zubaidi S, Tayem AA, et al. Diabetic macular edema (DME): dissecting pathogenesis, prognostication, diagnostic modalities along with current and futuristic therapeutic insights. Int J Retin Vitreous. 2024;10:83.","journal-title":"Int J Retin Vitreous"},{"key":"4825_CR26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00417-006-0516-y","volume":"245","author":"A Reichenbach","year":"2007","unstructured":"Reichenbach A, Wurm A, Pannicke T, Iandiev I, Wiedemann P, Bringmann A. M\u00fcller cells as players in retinal degeneration and edema. Graefes Arch Clin Exp Ophthalmol. 2007;245:627\u201336.","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04825-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04825-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04825-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:26:51Z","timestamp":1792409211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04825-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":26,"alternative-id":["4825"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04825-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article the funding section has been updated.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}